PMID- 7522547
OWN - NLM
STAT- MEDLINE
DCOM- 19941107
LR  - 20191031
IS  - 1049-8834 (Print)
IS  - 1049-8834 (Linking)
VI  - 14
IP  - 10
DP  - 1994 Oct
TI  - Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy 
      postmenopausal women.
PG  - 1586-93
AB  - Data in the literature suggest that circulating levels of lipoprotein(a) [Lp(a)] 
      and insulinlike growth factor I (IGF-I) respond similarly to therapy with growth 
      hormone, estrogen, or tamoxifen. To more clearly document these relations, we 
      designed a randomized, double-blind, placebo-controlled study of the effects of 
      tamoxifen and continuous estrogen on circulating levels of Lp(a), IGF-I, and IGF 
      binding protein 3 (IGFBP-3) in healthy postmenopausal women. Both estrogen and 
      tamoxifen decreased serum levels of IGF-I to 30% below baseline during the 3 
      months of treatment, while IGFBP-3 levels were unchanged. Plasma Lp(a) levels 
      decreased to 24% below baseline after 1 month of treatment with either estrogen 
      or tamoxifen (P < .05 for estrogen only); after 3 months Lp(a) decreased to 34% 
      below baseline with tamoxifen therapy (P < .05) but returned to only 16% below 
      baseline with estrogen. The correlation between Lp(a) and IGF-I was highly 
      significant (P < .0001). We conclude that (1) tamoxifen lowers plasma Lp(a) 
      levels in healthy postmenopausal women, (2) the suppressive effects of tamoxifen 
      and estrogen on circulating Lp(a) concentration diverge after the first month of 
      therapy, and (3) circulating levels of Lp(a) and IGF-I are strongly correlated 
      with each other, an indication that they may share regulatory influences.
FAU - Shewmon, D A
AU  - Shewmon DA
AD  - Department of Medicine, Medical Center of Central Massachusetts, Worcester.
FAU - Stock, J L
AU  - Stock JL
FAU - Rosen, C J
AU  - Rosen CJ
FAU - Heiniluoma, K M
AU  - Heiniluoma KM
FAU - Hogue, M M
AU  - Hogue MM
FAU - Morrison, A
AU  - Morrison A
FAU - Doyle, E M
AU  - Doyle EM
FAU - Ukena, T
AU  - Ukena T
FAU - Weale, V
AU  - Weale V
FAU - Baker, S
AU  - Baker S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arterioscler Thromb
JT  - Arteriosclerosis and thrombosis : a journal of vascular biology
JID - 9101388
RN  - 0 (Carrier Proteins)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Estrogens)
RN  - 0 (Insulin-Like Growth Factor Binding Proteins)
RN  - 0 (Lipoprotein(a))
RN  - 0 (Somatomedins)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Aged
MH  - Carrier Proteins/blood
MH  - Cholesterol, LDL/blood
MH  - Double-Blind Method
MH  - Estrogens/*therapeutic use
MH  - Female
MH  - Humans
MH  - Insulin-Like Growth Factor Binding Proteins
MH  - Insulin-Like Growth Factor I/analysis
MH  - Lipoprotein(a)/*blood
MH  - Middle Aged
MH  - Osmolar Concentration
MH  - Postmenopause/*blood
MH  - Reference Values
MH  - Somatomedins/metabolism
MH  - Tamoxifen/*therapeutic use
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
AID - 10.1161/01.atv.14.10.1586 [doi]
PST - ppublish
SO  - Arterioscler Thromb. 1994 Oct;14(10):1586-93. doi: 10.1161/01.atv.14.10.1586.